Modalis Therapeutics Corporation (JP:4883) has released an update.
Modalis Therapeutics Corporation reported a downturn in its financial results for the first half of 2024, showing no operating revenue and a loss per share of ¥21.98. The company’s total assets decreased to ¥1,409 million from ¥2,025 million at the end of the previous year, and they have not provided a forecast for the fiscal year citing the difficulty of accurate estimations. Dividends remained at zero, consistent with the previous fiscal year’s end.
For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.
